Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|May 7, 2020
5 Tips for Treating COVID-Related Anxiety
Author(s)Yujuan Choy, MD
A constellation of factors contributes to heightened anxiety symptoms associated with the pandemic. The author offers simple steps to help patients alleviate stress.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5